Compare Pfizer Inc (PFE) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Tripadvisor Inc Common Stock — how do they compare? Pfizer Inc trades at $28.17 (market cap $158.56B), while Tripadvisor Inc Common Stock trades at $8.67 (market cap $1.01B). The key difference: Pfizer Inc is far larger — about 157× Tripadvisor Inc Common Stock's market cap, and Pfizer Inc pays a 6.18% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Tripadvisor Inc Common Stock for 57 Days on average.
| PFE | TRIP | |
|---|---|---|
Market Cap | $158.56B | $1.01B |
Volume | 44,138,282 | 3,004,748 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $16.72 |
52-Week Low | $23.67 | $8.04 |
Typical Hold Time | 158 Days | 57 Days |
Enterprise Value | $210.06B | $1.06B |
Dividend Yield | 6.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
TripAdvisor (TRIP) trades at $8.69, up 0.7% on the day, but remains near its 52-week low of $8.27 (Defense World, 2026-09-25). The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported Q2 2026 earnings of $0.35 per share, missing the $0.375 estimate (Zacks Investment Research, 2026-08-06), while revenue trends show modest growth from $1.5B in 2022 to $1.9B in 2025. Analyst sentiment is cautious with a consensus price target of $13.58, implying significant upside potential from current levels.
The outlook for TRIP hinges on its ability to stabilize core business performance amid competitive pressures from AI-driven travel platforms. Investment opportunity lies in the discounted valuation relative to analyst targets, but risks include persistent earnings misses, declining net cash flow, and market share erosion. The completion of TheFork subsidiary sale could provide a near-term catalyst, but execution remains key for shareholder value creation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
